Ensysce Biosciences (NASDAQ:ENSC) versus CannAmerica Brands (OTCMKTS:CNNXF) Head-To-Head Contrast

Ensysce Biosciences (NASDAQ:ENSC) and CannAmerica Brands (OTCMKTS:CNNXF) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Profitability

This table compares Ensysce Biosciences and CannAmerica Brands’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
CannAmerica Brands	N/A	N/A	N/A

Institutional & Insider Ownership

5.6% of Ensysce Biosciences shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Ensysce Biosciences and CannAmerica Brands, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1	0	0	0	1.00
CannAmerica Brands	0	0	0	0	0.00

Given CannAmerica Brands’ higher possible upside, analysts clearly believe CannAmerica Brands is more favorable than Ensysce Biosciences.

Valuation and Earnings

This table compares Ensysce Biosciences and CannAmerica Brands”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07 million	1.33	-$10.18 million	($3.35)	-0.13
CannAmerica Brands	N/A	N/A	N/A	N/A	N/A

CannAmerica Brands has lower revenue, but higher earnings than Ensysce Biosciences.

About Ensysce Biosciences

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

About CannAmerica Brands

CannAmerica Brands Corp. owns a portfolio of brands of medical cannabis and recreational cannabis products. The company primarily builds and maximizes the value of its brands by promoting, marketing, and licensing brands through various distribution channels, including dispensaries, wholesalers, and distributors in the states of Colorado, Nevada, Oklahoma, and Massachusetts. It offers cannabis infused gummy products, disposable vape pens, distillate droppers, and shatter and wax concentrate products under the CannAmerica brand. The company is headquartered in Vancouver, Canada.